|
32
|
127
|
3s8iA |
The retroviral-like protease (rvp) domain of human ddi1 |
|
18
|
99
|
3sabA |
Crystal structure of wild-type hiv-1 protease in complex with af78 |
|
99
|
387
|
3s7mA |
Pyrazolyl and thienyl aminohydantoins as potent bace1 inhibitors |
|
102
|
387
|
3s7lA |
Pyrazolyl and thienyl aminohydantoins as potent bace1 inhibitors |
|
16
|
99
|
3s45A |
Wild-type hiv-2 protease with antiviral drug amprenavir |
|
88
|
387
|
3s2oA |
Fragment based discovery and optimisation of bace-1 inhibitors |
|
18
|
99
|
3s53A |
Hiv-1 protease triple mutants v32i, i47v, v82i with antiviral drug darunavir in space group p212121 |
|
90
|
387
|
3rviA |
Structure of bace-1 (beta-secretase) in complex with 2-((2-amino-6-o-tolylquinolin-3-yl)methyl)-n-(cyclohexylmethyl)pentanamide |
|
18
|
99
|
3s43B |
Hiv-1 protease triple mutants v32i, i47v, v82i with antiviral drug amprenavir |
|
88
|
387
|
3ru1A |
Structure of bace-1 (beta-secretase) in complex with 3-(2-aminoquinolin-3-yl)-n-(cyclohexylmethyl)propanamide |
|
19
|
99
|
3s54A |
Hiv-1 protease triple mutants v32i, i47v, v82i with antiviral drug darunavir in space group p21212 |
|
19
|
99
|
3s43A |
Hiv-1 protease triple mutants v32i, i47v, v82i with antiviral drug amprenavir |
|
17
|
99
|
3s56A |
Hiv-1 protease triple mutants v32i, i47v, v82i with antiviral drug saquinavir |
|
88
|
387
|
3rsvA |
Structure of bace-1 (beta-secretase) in complex with (r)-3-(2-amino-6-o-tolylquinolin-3-yl)-n-((r)-2,2-dimethyltetrahydro-2h-pyran-4-yl)-2-methylpropanamide |
|
94
|
387
|
3rsxA |
Structure of bace-1 (beta-secretase) in complex with 6-(thiophen-3-yl)quinolin-2-amine |
|
91
|
387
|
3rtmA |
Structure of bace-1 (beta-secretase) in complex with 3-(2-aminoquinolin-3-yl)-n-cyclohexyl-n-methylpropanamide |
|
90
|
387
|
3rthA |
Structure of bace-1 (beta-secretase) in complex with 6-(2-(3,3-dimethylbut-1-ynyl)phenyl)quinolin-2-amine |
|
92
|
387
|
3rtnA |
Structure of bace-1 (beta-secretase) in complex with 3-(2-amino-6-o-tolylquinolin-3-yl)-n-cyclohexylpropanamide |
|
84
|
330
|
3lzyA |
Crystal structure of endothiapesin in complex with xenon |
|
78
|
329
|
2vs2A |
Neutron diffraction structure of endothiapepsin in complex with a gem- diol inhibitor. |
|
18
|
99
|
5upjA |
Hiv-2 protease/u99283 complex |
|
91
|
389
|
5tolA |
Crystal structure of beta-site app-cleaving enzyme 1 complexed with n-(3-((4as,7as)-2-amino-4,4a,5,6-tetrahydro-7ah-furo[2,3-d][1,3]thiazin-7a-yl)-4-fluorophenyl)-5-bromo-2-pyridinecarboxamide |
|
82
|
339
|
5t4sA |
Novel approach of fragment-based lead discovery applied to renin inhibitors |
|
86
|
339
|
5sy2A |
Structure-based design of a new series of n-piperidin-3-ylpyrimidine-5-carboxamides as renin inhibitors |
|
89
|
337
|
5sy3A |
Structure-based design of a new series of n-piperidin-3-ylpyrimidine-5-carboxamides as renin inhibitors |
|
87
|
337
|
5sz9A |
Structure-based design of a new series of n-piperidin-3-ylpyrimidine-5-carboxamides as renin inhibitors |
|
82
|
330
|
5p7kA |
Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 317 |
|
83
|
330
|
5p25A |
Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 123 |
|
83
|
330
|
5p6eA |
Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 275 |
|
83
|
330
|
5p1xA |
Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 116 |
|
83
|
330
|
5p8oA |
Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 357 |
|
84
|
330
|
5p5kA |
Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 245 |
|
82
|
330
|
5p7iA |
Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 315 |
|
82
|
330
|
5p2lA |
Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 139 |
|
82
|
330
|
5p86A |
Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 339 |
|
84
|
330
|
5p51A |
Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 226 |
|
84
|
330
|
5p69A |
Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 270 |
|
82
|
330
|
5p87A |
Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 340 |
|
83
|
330
|
5p4eA |
Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 203 |
|
84
|
330
|
5p5aA |
Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 235 |
|
82
|
330
|
5p60A |
Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 261 |
|
83
|
330
|
5p74A |
Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 301 |
|
83
|
330
|
5p7yA |
Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 331 |
|
82
|
330
|
5p3xA |
Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 186 |
|
83
|
330
|
5p2qA |
Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 143 |
|
82
|
330
|
5p72A |
Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 299 |
|
84
|
330
|
5p2xA |
Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 150 |
|
84
|
330
|
5p53A |
Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 228 |
|
83
|
330
|
5p13A |
Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 86 |
|
84
|
330
|
5p78A |
Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 305 |
